Comparison of Proton Pump Inhibitor and H2 Receptor Blocker on Prevention of Bleeding From Iatrogenic Ulcer After Endoscopic Submucosal Dissection for Gastric Neoplasms: A Prospective Randomized Controlled Trial
Not Applicable
- Conditions
- Delayed Bleeding
- Interventions
- Drug: high dose proton pump inhibitorDrug: H2RB
- Registration Number
- NCT01179724
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
after endoscopic submucosal dissection(ESD) of early gastric cancer, conventional proton pump(PPI) inhibitors and H2 receptor antagonists have a controversial effect on preventing bleeding from artificial ulcers. the aim of this study was to investigate whether a stronger acid suppression (high dose PPI) more effectively prevents bleeding after ESD
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 206
Inclusion Criteria
- the patients who agreed informed consent
- gastric adenoma or early gastric cancer which is eligible for conventional ESD indication
Exclusion Criteria
- recent drug history of PPI, H2 rector antagonist, bismuth and antibiotics within 4 weeks
- recent drug history of anticoagulant or antiplatelet agent within 7 days
- s/p subtotal gastrectomy
- recurred gastric adenoma or cancer
- pregnant or breast feeding patients
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description high dose proton pump inhibitor high dose proton pump inhibitor - H2 receptor antagonist H2RB -
- Primary Outcome Measures
Name Time Method bleeding incidence after ESD time to occur delayed bleeding within one month after ESD
- Secondary Outcome Measures
Name Time Method the size of healing ulcer after ESD follow up endoscopy for the healing of iatrogenic ulcer after one month ESD
Trial Locations
- Locations (1)
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of